Home > Insider Trading > Filing (0000899243-21-034314)

Filing Details

Accession Number:: 0000899243-21-034314
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2021-08-26 19:20:33
Reporting Period:: 2021-08-09

Accepted Time:: 2021-08-26 19:20:33
Original Submission Date:: 2021-08-11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1789972	Cullinan Oncology Inc.	CGEM	Biological Products, (No Disgnostic Substances) (2836)	813867811

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1837456	Leigh Zawel	C/O Cullinan Oncology, Inc. One Main Street, Suite 520 Cambridge MA 02142	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-08-09	19,504	$26.52	130,256	No	4	S	Direct
Common Stock	Disposition	2021-08-09	1,700	$27.11	128,556	No	4	S	Direct
Common Stock	Disposition	2021-08-10	1,906	$26.50	126,650	No	4	S	Direct
Common Stock	Disposition	2021-08-10	3,191	$27.34	123,459	No	4	S	Direct
Common Stock	Disposition	2021-08-10	1,817	$28.49	121,642	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.